Analysts Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $12.75

NeoGenomics, Inc. (NASDAQ:NEO) has been given an average rating of “Hold” by the twelve ratings firms that are presently covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $12.75.

NEO has been the topic of several research reports. Needham & Company LLC dropped their target price on NeoGenomics from $8.50 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, July 29th. William Blair reissued a “market perform” rating on shares of NeoGenomics in a report on Tuesday, July 29th. Wall Street Zen raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Tuesday, May 13th. The Goldman Sachs Group lowered their price objective on NeoGenomics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. Finally, Piper Sandler set a $11.00 price objective on NeoGenomics and gave the company an “overweight” rating in a report on Monday, August 4th.

Insider Activity at NeoGenomics

In other news, Director Michael Aaron Kelly acquired 5,000 shares of NeoGenomics stock in a transaction on Tuesday, May 27th. The stock was bought at an average price of $7.60 per share, for a total transaction of $38,000.00. Following the transaction, the director owned 5,000 shares of the company’s stock, valued at $38,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Warren Stone acquired 5,700 shares of NeoGenomics stock in a transaction on Monday, May 12th. The stock was purchased at an average price of $8.58 per share, with a total value of $48,906.00. Following the transaction, the chief operating officer directly owned 108,280 shares in the company, valued at approximately $929,042.40. This trade represents a 5.56% increase in their position. The disclosure for this purchase can be found here. 2.40% of the stock is owned by corporate insiders.

Institutional Trading of NeoGenomics

Hedge funds have recently modified their holdings of the company. Sterling Capital Management LLC lifted its position in shares of NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company’s stock worth $61,000 after buying an additional 3,289 shares during the period. Brooklyn Investment Group bought a new position in shares of NeoGenomics during the 1st quarter worth approximately $35,000. CWM LLC lifted its position in shares of NeoGenomics by 42.6% during the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock worth $60,000 after buying an additional 1,883 shares during the period. AlphaQuest LLC bought a new position in shares of NeoGenomics during the 1st quarter worth approximately $60,000. Finally, Moors & Cabot Inc. acquired a new stake in NeoGenomics during the 1st quarter valued at $95,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

Shares of NEO stock opened at $5.80 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.92 and a quick ratio of 3.58. NeoGenomics has a fifty-two week low of $4.72 and a fifty-two week high of $19.11. The stock’s 50-day moving average is $6.82 and its two-hundred day moving average is $8.98. The firm has a market cap of $749.24 million, a P/E ratio of -7.16 and a beta of 1.54.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.